Original Communication| Volume 147, ISSUE 3, P405-414, March 2010

Gene-expression phenotypes for vascular invasiveness of hepatocellular carcinomas

Published:November 30, 2009DOI:


      Gross vascular invasion is a well-established prognostic indicator in hepatocellular carcinoma (HCC), but the biological significance of microscopic invasion remains unclear.


      Curatively resected primary HCCs were classified retrospectively into 3 groups: HCCs without vascular invasion (V0), HCCs with microvascular invasion (V1), and HCCs with macrovascular invasion (V2). Microarray profiling of patients with V0, V1, and V2 using Jonckheere-Terpstra (JT) tests and Wilcoxon rank sum tests was performed.


      Distinct patterns of gene expression were demonstrated between V0 and V2 groups; less (L) and highly (H) invasive phenotypes, respectively. It is noteworthy that 2 dendrograms by the hierarchical clustering provided exactly the same assignment results for V1 cases that were thus separated into L and H gene-expression phenotypes. Marked differences were found in overall (P < .001) and tumor-free survival (P < .001) between L and H gene-expression phenotypes. Multivariate analyses indicated that the phenotypes of the patterns of gene expression, rather than the clinicopathologic markers of vascular invasion, were independent predictors of tumor recurrence (P = .031). Using the gene-expression patterns identified by both JT and Wilcoxon rank sum test analyses, other V1 cases validated these differences in tumor-free survivals between gene-expression phenotypes within the group (P = .039).


      Gene profiling suggested that microvascular invasiveness consisted of a classable mixture of 2 distinct phenotypes. Thus, gene-array analyses may have clinical benefit, because they may in fact be more predictive than other clinical factors.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Ince N.
        • Wands J.R.
        The increasing incidence of hepatocellular carcinoma.
        N Engl J Med. 1999; 340: 798-799
        • Arii S.
        • Yamaoka Y.
        • Futagawa S.
        • Inoue K.
        • Kobayashi K.
        • Kojiro M.
        • et al.
        Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan.
        Hepatology. 2000; 32: 1224-1229
        • Tanaka S.
        • Noguchi N.
        • Ochiai T.
        • Kudo A.
        • Nakamura N.
        • Ito K.
        • et al.
        Outdcomes and recurrence of initially resection of hepatocellular carcinoma meeting Milan criteria: rationale for partial hepatectomy as first strategy.
        J Am Coll Surg. 2007; 204: 1-6
        • Kumada T.
        • Nakano S.
        • Takeda I.
        • Sugiyama K.
        • Osada T.
        • Kiriyama S.
        • et al.
        Patterns of recurrence after initial treatment in patients with small hepatocellular carcinoma.
        Hepatology. 1997; 25: 87-92
        • Izumi R.
        • Shimizu K.
        • Ii T.
        • Yagi M.
        • Matsui O.
        • Nonomura A.
        • et al.
        Prognostic factors of hepatocellular carcinoma in patients undergoing hepatic resection.
        Gastroenterology. 1994; 106: 720-727
        • Shimada M.
        • Takenaka K.
        • Gion T.
        • Fujiwara Y.
        • Kajiyama K.
        • Maeda T.
        • et al.
        Prognosis of recurrent hepatocellular carcinoma: a 10-year surgical experience in Japan.
        Gastroenterology. 1996; 111: 720-726
        • Poon R.T.
        • Fan S.T.
        • Lo C.M.
        • Liu C.L.
        • Wong J.
        Intrahepatic recurrence after curative resection of hepatocellular carcinoma: long-term results of treatment and prognostic factors.
        Ann Surg. 1999; 229: 216-222
        • Ohkubo T.
        • Yamamoto J.
        • Sugawara Y.
        • Shimada K.
        • Yamasaki S.
        • Makuuchi M.
        • et al.
        Surgical results for hepatocellular carcinoma with macroscopic portal vein tumor thrombosis.
        J Am Coll Surg. 2000; 191: 657-660
        • Iizuka N.
        • Oka M.
        • Yamada-Okabe H.
        • Nishida M.
        • Maeda Y.
        • Mori N.
        • et al.
        Oligonucleotide microarray for prediction of early intrahepatic recurrence of hepatocellular carcinoma after curative resection.
        Lancet. 2003; 361: 923-929
        • Thomas M.B.
        • Abbruzzese J.L.
        Opportunities for targeted therapies in hepatocellular carcinoma.
        J Clin Oncol. 2005; 23: 8093-8108
        • Tanaka S.
        • Arii S.
        • Yasen M.
        • Mogushi K.
        • Su N.T.
        • Zhao C.
        • et al.
        Aurora kinase B is a predictive factor for aggressive recurrence of hepatocellular carcinoma after curative hepatectomy.
        Br J Surg. 2008; 95: 611-619
        • Dahlquist K.D.
        • Salomonis N.
        • Vranizan K.
        • Lawlor S.C.
        • Conklin B.R.
        GenMAPP, a new tool for viewing and analyzing microarray data on biological pathways.
        Nat Genet. 2002; 31: 19-20
        • Gadea B.B.
        • Ruderman J.V.
        Aurora B is required for mitotic chromatin-induced phosphorylation of Op18/Stathmin.
        Proc Natl Acad Sci U S A. 2006; 103: 4493-4498
        • Liu S.T.
        • Rattner J.B.
        • Jablonski S.A.
        • Yen T.J.
        Mapping the assembly pathways that specify formation of the trilaminar kinetochore plates in human cells.
        J Cell Biol. 2006; 175: 41-53
        • Ayoub N.
        • Jeyasekharan A.D.
        • Bernal J.A.
        • Venkitaraman A.R.
        HP1-beta mobilization promotes chromatin changes that initiate the DNA damage response.
        Nature. 2008; 453: 682-686
        • Chalamalasetty R.B.
        • Hümmer S.
        • Nigg E.A.
        • Silljé H.H.
        Influence of human Ect2 depletion and overexpression on cleavage furrow formation and abscission.
        J Cell Sci. 2006; 119: 3008-3019
        • Arii S.
        • Mise M.
        • Harada T.
        • Furutani M.
        • Ishigami S.
        • Niwano M.
        • et al.
        Overexpression of matrix metalloproteinase 9 gene in hepatocellular carcinoma with invasive potential.
        Hepatology. 1996; 24: 316-322
        • Tanaka S.
        • Mori M.
        • Sakamoto Y.
        • Makuuchi M.
        • Sugimachi K.
        • Wands J.R.
        Biologic significance of angiopoietin-2 expression in human hepatocellular carcinoma.
        J Clin Invest. 1999; 103: 341-345
        • Liu S.H.
        • Lin C.Y.
        • Peng S.Y.
        • Jeng Y.M.
        • Pan H.W.
        • Lai P.L.
        • et al.
        Down-regulation of annexin A10 in hepatocellular carcinoma is associated with vascular invasion, early recurrence, and poor prognosis in synergy with p53 mutation.
        Am J Pathol. 2002; 160: 1831-1837
        • Ho M.C.
        • Lin J.J.
        • Chen C.N.
        • Chen C.C.
        • Lee H.
        • Yang C.Y.
        • et al.
        A gene expression profile for vascular invasion can predict the recurrence after resection of hepatocellular carcinoma: a microarray approach.
        Ann Surg Oncol. 2006; 13: 1474-1484
        • Kaposi-Novak P.
        • Lee J.S.
        • Gomez-Quiroz L.
        • Coulouarn C.
        • Factor V.M.
        • Thorgeirsson S.S.
        Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype.
        J Clin Invest. 2006; 116: 1582-1595
        • Nakashima Y.
        • Nakashima O.
        • Tanaka M.
        • Okuda K.
        • Nakashima M.
        • Kojiro M.
        Portal vein invasion and intrahepatic micrometastasis in small hepatocellular carcinoma by gross type.
        Hepatol Res. 2003; 26: 142-147
        • Mazzaferro V.
        • Regalia E.
        • Doci R.
        • Andreola S.
        • Pulvirenti A.
        • Bozzetti F.
        • et al.
        Liver transplantation for the treatment of small hepatocellular carcinoma in patients with cirrhosis.
        N Engl J Med. 1996; 334: 693-699
        • Todo S.
        • Furukawa H.
        Japanese Study Group on Organ Transplantation. Living donor liver transplantation for adult patients with hepatocellular carcinoma: experience in Japan.
        Ann Surg. 2004; 240: 451-459
        • Shetty K.
        • Timmins K.
        • Brensinger C.
        • Furth E.E.
        • Rattan S.
        • Sun W.
        • et al.
        Liver transplantation for hepatocellular carcinoma validation of present selection criteria in predicting outcome.
        Liver Transpl. 2004; 10: 911-918
        • Shah S.A.
        • Tan J.C.
        • McGilvray I.D.
        • Cattral M.S.
        • Levy G.A.
        • Greig P.D.
        • et al.
        Does microvascular invasion affect outcomes after liver transplantation for HCC? A histopathological analysis of 155 consecutive explants.
        J Gastrointest Surg. 2007; 11: 464-471
        • Sala M.
        • Fuster J.
        • Llovet J.M.
        • Navasa M.
        • Solé M.
        • Varela M.
        • et al.
        High pathological risk of recurrence after surgical resection for hepatocellular carcinoma: an indication for salvage liver transplantation.
        Liver Transpl. 2004; 10: 1294-1300
        • Vader G.
        • Medema R.H.
        • Lens S.M.
        The chromosomal passenger complex: guiding Aurora-B through mitosis.
        J Cell Biol. 2006; 173: 833-837
        • Takahashi K.
        • Yamada H.
        • Yanagida M.
        Fission yeast minichromosome loss mutants mis cause lethal aneuploidy and replication abnormality.
        Mol Biol Cell. 1994; 5: 1145-1158
        • Rajagopalan H.
        • Jallepalli P.V.
        • Rago C.
        • Velculescu V.E.
        • Kinzler K.W.
        • Vogelstein B.
        • et al.
        Inactivation of hCDC4 can cause chromosomal instability.
        Nature. 2004; 428: 77-81
        • Girdler F.
        • Gascoigne K.E.
        • Eyers P.A.
        • Hartmuth S.
        • Crafter C.
        • Foote K.M.
        • et al.
        Validating Aurora B as an anti-cancer drug target.
        J Cell Sci. 2006; 119: 3664-3675
      1. Aihara A, Tanaka S, Yasen M, Matsumura S, Mitsunori Y, Murakata A, et al. The selective Aurora B kinase inhibitor AZD1152 as a novel treatment for hepatocellular carcinoma. J Hepatol. In press.